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Abstract
It is widely believed that the alveolar epithelium is unresponsive to LPS, in the absence of serum, due to low expression of
TLR4 and CD14. Furthermore, the responsiveness of the epithelium to TLR-2 ligands is also poorly understood. We
hypothesised that human alveolar type I (ATI) and type II (ATII) epithelial cells were responsive to TLR2 and TLR4 ligands
(MALP-2 and LPS respectively), expressed the necessary TLRs and co-receptors (CD14 and MD2) and released distinct
profiles of cytokines via differential activation of MAP kinases. Primary ATII cells and alveolar macrophages and an
immortalised ATI cell line (TT1) elicited CD14 and MD2-dependent responses to LPS which did not require the addition of
exogenous soluble CD14. TT1 and primary ATII cells expressed CD14 whereas A549 cells did not, as confirmed by flow
cytometry. Following LPS and MALP-2 exposure, macrophages and ATII cells released significant amounts of TNFa, IL-8 and
MCP-1 whereas TT1 cells only released IL-8 and MCP-1. P38, ERK and JNK were involved in MALP-2 and LPS-induced cytokine
release from all three cell types. However, ERK and JNK were significantly more important than p38 in cytokine release from
macrophages whereas all three were similarly involved in LPS-induced mediator release from TT1 cells. In ATII cells, JNK was
significantly more important than p38 and ERK in LPS-induced MCP-1 release. MALP-2 and LPS exposure stimulated TLR4
protein expression in all three cell types; significantly more so in ATII cells than macrophages and TT1 cells. In conclusion,
this is the first study describing the expression of CD14 on, and TLR2 and 4 signalling in, primary human ATII cells and ATI
cells; suggesting that differential activation of MAP kinases, cytokine secretion and TLR4 expression by the alveolar
epithelium and macrophages is important in orchestrating a co-ordinated response to inhaled pathogens.
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Introduction
The respiratory tract is one of the primary routes of entry to the
body for invading pathogens. As such, it requires tightly regulated
mechanisms with which to respond to a potentially endless spectrum
of microbes. One line of defence is the expression of a family of
receptors known as the Toll-like receptors (TLRs) that are able to
recogniseavarietyofmicrobialmarkers.Atpresent11receptorshave
been identified in man, each of which recognises distinct pathogen-
associated molecular patterns (PAMPs) [1]. These receptors can be
divided by the source of the PAMPs that they recognise. Thus, TLRs
1, 2, 4, 5 and 6 recognise largely bacterial pathogens, whereas TLRs
3, 7 and 8 recognise predominantly viral motifs [2].
TLR-2 recognises a broad spectrum of microbial products such as
peptidoglycan from gram-positive bacteria, bacterial lipoproteins,
lipoarabinomannan from mycobacteria and yeast cellwalls. Its broad
range of ligand specificity may be accountable to its ability to
heterodimerise with two other TLRs, TLR-1 [3] and TLR-6 [4]. In
this way, these heterodimers confer specificity for a certain subset of
the aforementioned ligands. For example, the TLR-2/6 heterodimer
specifically recognises the mycoplasmal lipoprotein, macrophage-
activating lipopeptide 2 kDa (MALP-2). This selectivity has been
shown to be due to the ability of TLR-6 to differentiate between
triacylated bacterial lipoproteins and the diacylated MALP-2. In mice
lacking TLR-2, macrophages were unresponsive to both bacterial
and mycoplasmal lipoproteins whereas TLR-6-deficient mice were
only unresponsive to MALP-2 [4].
TLR4 is the primary receptor for recognition of lipopolysac-
charide (LPS), found on gram negative bacteria, and was the first
mammalian TLR to be characterised [5]. TLR4 signalling
requires a number of accessory proteins to initiate a signal. A
key component of the TLR4 receptor cluster is MD-2. MD-2 is a
soluble protein that binds to the extracellular domain of TLR4
and is essential for LPS recognition [6]. Studies of the receptor
structure have demonstrated that MD-2 binds directly to LPS
causing an allosteric change in that facilitates its binding to a
second TLR4 protein thus forming a receptor dimer [7,8]. These
studies also suggest that LPS does not directly bind to the TLR4
receptor, thus explaining the obligate requirement for MD-2.
Another important TLR4 accessory protein is CD14, a high
affinity receptor that is found on the surface of cells such as
macrophages and monocytes [9] in a GPI-anchored form, or
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21827extracellularly in a soluble form [10]. CD14, upon binding to LPS,
facilitates the transfer of LPS to the TLR4/MD-2 complex; studies
have demonstrated that this is particularly important in facilitating
TLR4 responsiveness to very low levels (,1 ng/ml) of LPS [11].
CD14 has also been implicated in TLR-2 signalling. Studies have
demonstrated that CD14 can bind to lipoproteins [12] and potentiate
the activation of NF-kB following TLR2/1 ligation [13].
Previous studies in animals have described the presence of TLR2
and TLR4 in the lung and have demonstrated their potential
importance in a number of diseases [14–16]. However, the expression
of TLR2 and 4 and their associated accessory proteins in the
peripheral alveolar region of the lung remains unclear. The expression
of TLR2, TLR4 and CD14 by alveolar macrophages and monocytes
has been previously demonstrated [17,18]. However, expression of
TLR4 and CD14 by the alveolar epithelium is still debated. Studies
using the A549 adenocarcinoma cell line as a model of human
alveolar type II epithelial cells have demonstrated surface and cytosolic
expression of TLR4 and CD14 [19] yet in the absence of serum in the
cell culture medium, A549 cells are unresponsive, suggesting an
obligate need for exogenous soluble CD14 in order to elicit a TLR4
response [20]. In similar studies we have previously shown that TLR2
and TLR4 mRNA and protein can be detected in primary human
alveolar type II epithelial (ATII) cells [21]. However, in marked
difference to studies using A549 cells, we have demonstrated that
primary human ATII cells are responsive to TLR4 ligation and
secrete a number of cytokines and chemokines in the absence of serum
[22,23]. This suggests that, unlike A549 cells, primary human ATII
cells express the necessary accessory proteins for TLR4 signalling,
although this has not yet been investigated and remains unknown.
To date, studies of the TLR responsiveness of the human alveolar
epithelium have focused on ATII cells. Despite being the predominant
cell in the alveolar space by number, ATII cells only cover 5% of the
surface. The remaining 95% is covered by large attenuated alveolar
type I epithelial (ATI) cells. It may therefore be hypothesised that this
cell type is more likely to encounter mi c r o b e st h a nA T I Ic e l l s ;h o w e v e r ,
d u et ot h e i rf r a g i l en a t u r ei ti sn o tp o s s i b l et oi s o l a t et h e s ec e l l sf r o m
human lung tissue and thus the expression of Toll-like receptors on this
cell type has never been investigated. We have recently created and
fully characterised an immortalised ATI cell line [24] which allows us
to explore the reactivity of this cell type in vitro; thereby giving a unique
insight in to the innate immune response of the alveolar epithelium.
In the following study we compared the TLR2 and TLR4
responses of the three major alveolar cell types: macrophages, ATI
and ATII cells. In addition we sought to elucidate the role of the
accessory proteins CD14 and MD-2 in TLR2 and TLR4 signalling in
the alveolus. Our previous studies of LPS-exposed primary human
ATII cells and alveolar macrophages show a differential response by
these cells to TLR4 activation [22] suggesting that there could be
differences in both TLR4 receptor and accessory protein expression
and subsequent cell signalling pathways activated in these cells.
We hypothesised that the differential response of alveolar
macrophages and ATII cells to TLR2 and TLR4 ligation is due to
differential expression of these receptors and their accessory
proteins and thus differential activation of MAP kinase signalling
pathways. In addition, we suggest that ATI cells are also sensitive
to TLR ligands and thus express TLR2 and TLR4 and the
necessary accessory proteins.
Results
LPS and MALP-2 induce differential mediator release
from macrophages, TT1 and ATII cells but not A549 cells
The effect of increasing concentrations of the TLR4 agonist,
LPS, on TNFa, MCP-1 and IL-8 release from primary human
alveolar macrophages and TT1 and ATII cells was investigated
(Figure 1). LPS caused a concentration dependent increase in
release of TNFa (P,0.0001), MCP-1 (P,0.0002) and IL-8
(P,0.0001) from both alveolar macrophages and ATII cells,
however only MCP-1 and IL-8 were released from TT1 cells in
significant amounts (P,0.0001). TNFa release from alveolar
macrophages following LPS exposure was greater than that
observed for ATII cells (P,0.02), while MCP-1 release by TT1
and ATII cells was significantly greater than release from alveolar
macrophages (P,0.0001). TT1 cells released significantly more
MCP-1 than IL-8 in response to LPS (P,0.05) whereas ATII cells
released significantly more IL-8 than MCP-1 (P,0.001). As
demonstrated by others, A549 cells were not responsive to LPS at
the concentrations used in this study either in the absence or
presence of serum.
MALP-2 exposure induced a significant dose dependent
increase in MCP-1 (P,0.0001) and IL-8 (P,0.0001) from all
three cell types whereas TNFa was only released by alveolar
macrophages and ATII cells (P,0.0001; Figure 2). MALP-2
induced a significantly greater release of all three mediators from
alveolar macrophages compared to LPS (P,0.002). MALP-2
induced significantly more MCP-1 release from TT1 and ATII
cells compared to alveolar macrophages (P,0.0001) whereas
release of IL-8 from alveolar macrophages and ATII cells was
significantly greater than that from TT1 cells (P,0.0001).
Serum amplifies the cellular response to LPS but not
MALP-2
The addition of serum to the culture medium significantly
enhanced IL-8 and MCP-1 release from all three cell types
(Figure 1; P,0.001). Similarly, LPS-induced TNFa release from
macrophages and ATII cells was also significantly increased in the
presence of serum (P,0.0001). As before, LPS did not induce
TNFa release from TT1 cells even in the presence of serum. The
addition of serum to culture conditions during exposure to MALP-
2 did not amplify release of any of the mediators from each of the
three cell types (Figure 2).
Epithelial cells express CD14 but A549 cells do not
Cell surface expression of CD14 was assessed in TT1, ATII and
A549 cells using flow cytometry. Both TT1 and ATII cells
expressed CD14 whereas A549 cells did not (Figure 3). Further-
more, primary human ATII cells expressed significantly more
CD14 than TT1 cells (P,0.007; Figure 4).
MD2 and CD14 are involved in the LPS but not the MALP-
2 response
Neutralisation of MD2 and CD14 significantly inhibited LPS-
induced cytokine and chemokine release in all three cell types
(P,0.002; Figure 5); almost completely abolishing the LPS
response. In contrast, neutralisation of CD14 or MD2 had no
effect on MALP-2-induced mediator release from all three cell
types (Figure 6). Incubation of cells with the relevant IgG isotype
control had no effect on LPS-induced mediator release.
LPS and MALP-2-induced mediator release involves p38,
JNK and ERK
Inhibition of P38, ERK or JNK all caused an inhibition of LPS
(Figure 7) and MALP-2 (Figure 8) -induced cytokine secretion
from all three cell types. All three MAP kinase inhibitors had a
similar profile of action against LPS-induced TNFa, MCP-1 and
IL-8 release from alveolar macrophages; blockade of JNK and
ERK caused significantly greater inhibition of mediator release
TLR Responses to Bacteria in the Human Alveolus
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greater effect on mediator release from macrophages than TT1
and ATII cells (P,0.05). In ATII cells, the profile of inhibition of
the MAP kinases on TNFa, IL-8 and MCP-1 release was markedly
different. There was no significant difference in the effect of the
inhibitor on TNFa release and IL-8 release from ATII cells or
MCP-1 and IL-8 release from TT1 cells. However, Inhibition of
JNK had a significantly greater effect on MCP-1 release than p38
and ERK inhibition (P,0.0001) and was significantly more
effective at inhibiting MCP-1 than TNFa release (P,0.002).
Similarly to observations following LPS exposure, JNK and
ERK inhibitors significantly inhibited MALP-2-induced TNFa,
MCP-1 (P,0.0001) and IL-8 (P,0.05) release from alveolar
macrophages more than the p38 inhibitor. Similarly JNK and
ERK inhibition significantly reduced MALP-2-induced MCP-1
(P,0.005) and IL-8 (P,0.05) more than p38 inhibition. In ATII
cells, JNK and ERK inhibitors were significantly more effective
than the p38 inhibitor in blocking MALP-2-induced IL-8 release,
whereas there was no significant difference between the three
inhibitors in inhibiting MCP-1 release.
LPS and MALP-2 differentially induce TLR4 protein
expression by alveolar macrophages, TT1 cells and ATII
cells
LPS and MALP-2-induced TLR expression was measured using
image analysis of immunofluorescent confocal images (Figures 9
and 10 respectively). Following exposure to LPS, all three cell
types significantly up-regulated TLR4 expression in a time
dependent manner (Figure 11A; P,0.0001). ATII TLR4
expression significantly increased after 30 minutes (P,0.05) and
by three hours had increased 10-fold (P,0.0001). Immunoloca-
lisation showed that expression of TLR4 in ATII cells was diffuse
throughout the cell but appeared most intense in the perinuclear
region (Figure 12). When the above experiments were repeated on
macrophages, obtained from the same subjects, as well as the TT1
cell line, it was shown that both TT1 and macrophages cells
expressed low levels of TLR4 basally. Following LPS exposure,
macrophage TLR4 expression increased significantly after
30 minutes (P,0.05) and by three hours was 5.5 fold greater
than baseline (P,0.0001). Using confocal microscopy, TLR4
could clearly be seen on the cell surface at early time points as well
as intracellularly. However, at later time points expression of the
receptors was markedly increased in the cytoplasm and perinu-
clear region (Figure 12). In TT1 cells expression was significantly
greater after 1 hour (P,0.05) and by three hours was 2.5-fold
greater than at time zero (P,0.0001).
ATII cells expressed significantly more TLR4 than TT1 cells after
one hour exposure (P,0.0001) and alveolar macrophages after two
hours (P,0.0001). By two hours, TT1 TLR4 expression was also
significantly lower than macrophage expression (P,0.0001). Due to
the low level of expression by TT1 cells, it was not possible to clearly
visualise the cellular localisation of expression.
Exposure to MALP-2 (Figure 11B) also induced a significant
time-dependent increase in TLR4 expression in ATII cells,
macrophages (P,0.0001) and TT1 cells (P,0.05). Similar to
observations following LPS exposure, TLR4 expression was up-
regulated in ATII cells significantly more than macrophages and
TT1 cells by one hour (P,0.002). Furthermore, by three hours
Figure 1. Effect of LPS and serum on cytokine release from alveolar macrophages, ATII and TT1 cells. Cells were exposed to LPS (1–
100 ng/ml) in the presence and absence of serum for 24 hours. Conditioned media was then aspirated and TNFa, MCP-1 and IL-8 release measured
by Luminex. Data expressed as mean 6 SE (n=6 subjects). **P,0.001, ***P,0.0002.
doi:10.1371/journal.pone.0021827.g001
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cell TLR4 expression (P,0.0002).
Despite using a number of different antibodies and cell staining
protocols, it was not possible to visualise TLR2 protein in any of
the cells types. It was therefore not possible to quantify the effects
of LPS and MALP-2 exposure on TLR2 expression.
Discussion
These studies demonstrate for the first time, that human
alveolar epithelial cells constitutively express CD14 and MD-2,
accessory proteins which are essential for TLR4 signalling. We
have also demonstrated that LPS and MALP-2, TLR4 and TLR2
ligands respectively, can rapidly induce a marked increase in the
expression of TLR4 protein in human alveolar macrophages and
ATII cells, and to a lesser extent, TT1 cells and distinct differences
in the cytokine responses of these three cell types. This comparison
of the innate immune response of primary human alveolar
epithelial cells and macrophages obtained from the same subjects
provides a unique insight into the differential activation of resident
and migratory cells in the respiratory units. Furthermore, the study
of a newly generated cell line derived from human alveolar type I
Figure 2. Effect of MALP-2 and serum on cytokine release from alveolar macrophages, ATII and TT1 cells. Cells were exposed to MALP-
2 (1–100 ng/ml) in the presence and absence of serum for 24 hours. Conditioned media was then aspirated and TNFa, MCP-1 and IL-8 release
measured by Luminex. Data expressed as mean 6 SE (n=6 subjects). **P,0.002, ***P,0.0001.
doi:10.1371/journal.pone.0021827.g002
Figure 3. FACS analysis of cell surface CD14 expression on primary human ATII cells, immortalised TT1 cells and A549 cells. Cells
were immunostained with FITC-labelled anti CD-14 antibody and expression measured using flow cytometry. Representative hisotgrams demonstrate
that ATII cells (A) and TT1 cells (B) express CD14 whereas A549 cells (C) do not.
doi:10.1371/journal.pone.0021827.g003
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study in vitro due to its fragile nature preventing it from being
isolated in primary culture, further adds to the uniqueness of this
study. Thus, we have demonstrated that alveolar epithelial cells
can respond to TLR2 and TLR4 ligands in much the same way as
do macrophages in an environment relatively low in serum
proteins.
Our studies have demonstrated that the profile of cytokine
release from alveolar macrophages, TT1 and ATII cells differs in
response to TLR2 and TLR4 ligation. We demonstrated that
alveolar macrophages were the primary source of TNFa; ATII
cells released approximately half the amount of macrophages and
TT1 cells released none at all. The observed release of TNFa by
ATII cells is somewhat controversial as there are a number of
studies suggesting that the alveolar epithelium does not release
TNFa [25,26]. However our results support findings of others
demonstrating that under inflammatory and pathological condi-
tions ATII cells from rats [27] and humans [28] can indeed release
TNFa. Our study suggests that under basal conditions, macro-
phages are the sole source of TNFa; however following bacterial
colonisation the alveolar epithelium can release TNFa albeit at
much lower levels than alveolar macrophages. Following our
observations of TLR2 and TLR4-induced TNFa release from
primary human ATII cells, we were surprised to discover that TT1
cells did not release any following LPS or MALP-2 exposure. We
have previously demonstrated that TNFa can act in an autocrine
manner to trigger further release of mediators from ATII cells
[22]. It could therefore be postulated that this response may not be
desirable in TT1 cells which cover over 95% of the alveolar
surface. Such a response in these cells could lead to an excessive
inflammatory response that may be deleterious to the host. We
also demonstrated that the epithelium is a richer source of
chemokines than macrophages following MALP-2 ligation; a
finding we have previously demonstrated in ATII cells following
LPS exposure [22]. These results further support our hypothesis
that leukocyte recruitment during bacterial infection may
primarily be due to the robust response of the alveolar epithelium
rather than the already resident alveolar macrophages.
Much of the previous research on the innate immune response
of the human alveolar region has relied on the use of the A549
adenocarcinoma cell line as a model of ATII cells. These studies
have led to the general belief that, in the absence of serum, the
alveolar epithelium is unresponsive to LPS despite these cells
expressing TLR4 [20]. Our studies using primary human ATII
cells and ATI cells immortalised from normal primary human
alveolar epithelial cells clearly demonstrate that this is not the case.
We demonstrated in our studies that both TT1 and ATII cells are
exquisitely sensitive to LPS exposure and release cytokines and
chemokines in response to levels as low as 1 ng/ml even in the
Figure 4. Comparative expression of CD14 on primary human
ATII cells, immortalised TT1 cells and A549 cells. Cells were
immunostained with CD14 and cells surface expression measured using
flow cytometry. The ratio of median fluorescent intensity of CD14
staining relative to IgG control was calculated for all cells. Results
demonstrated that both ATII cells and TT1 cells express CD14 whereas
A549 cells do not. Furthermore, ATII cells had significantly higher CD14
staining than TT1 cells. Data expressed as mean 6 SE (n=4 subjects).
**P,0.007.
doi:10.1371/journal.pone.0021827.g004
Figure 5. Effect of CD-14 and MD2 neutralisation on LPS-
induced cytokine release from alveolar macrophages, ATII and
TT1 cells. Cells were pre-incubated with an anti-CD14 or anti-MD2
neutralising antibody for 1 hr before exposure to 100 ng/ml LPS for
24 hours. TNFa, MCP-1 and IL-8 release was measured by Luminex. Data
expressed as mean 6 SE (n=4 subjects). **P,0.002, ***P,0.0001. The
relevant IgG isotype was used as a control and had no effect on LPS-
induced mediator release.
doi:10.1371/journal.pone.0021827.g005
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responsiveness and the obligate need for serum (a source of soluble
CD14) is that cells of an epithelial origin do not constitutively
express functional levels of CD14 [29,30]. We have confirmed this
in our studies; using flow cytometry we demonstrated that the
A549 adenocarcinoma cells line does not express CD14. However,
a significant finding in our studies is that both TT1 cells and
primary human ATII cells express CD14 constitutively, and that
neutralisation of CD14 with antibodies blocks LPS-induced release
of IL-8 and MCP-1. This was also the case for alveolar
macrophages. Despite epithelial expression of CD14 we do
however demonstrate that the addition of serum, a rich source
of soluble CD14, further amplifies the response to LPS. This
ability of exogenous soluble CD14 may be particularly important
in conditions such as acute lung injury where there is significant
microvascular leakage in to the alveolar space.
In these studies we also investigated the effect of serum and
CD14 neutralisation on MALP-2 induced mediator release as
there is currently debate as to whether CD14 is involved in
facilitating TLR-2 signalling. It is widely accepted that CD14 is
involved in the signalling of triacylated lipoproteins through the
Figure 6. Effect of CD-14 and MD2 neutralisation on MALP-2-
induced cytokine release from alveolar macrophages, ATII and
TT1 cells. Cells were pre-incubated with an anti-CD14 or anti-MD2
neutralising antibody for 1 hr before exposure to 100 ng/ml MALP-2 for
24 hours. TNFa, MCP-1 and IL-8 release was measured by Luminex. Data
expressed as mean 6 SE (n=4 subjects). The relevant IgG isotype was
used as a control and had no effect on LPS-induced mediator release.
doi:10.1371/journal.pone.0021827.g006
Figure 7. Inhibition of LPS-induced cytokine release from
alveolar macrophages ATII and TT1 cells by MAP kinase
inhibitors. Cells were pre-incubated for 30 min with 10 mMo f
inhibitors of p38 (SB202190), JNK (SP600125) or ERK (PD98059) before
exposure to 100 ng/ml LPS for 24 hours. TNFa (A), MCP-1 (B) and IL-8
(C) release were measured by Luminex. Data expressed as mean 6 SE
(n=4 subjects). *P,0.05, **P,0.002, ***P,0.0002.
doi:10.1371/journal.pone.0021827.g007
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signalling of diacylated lipoproteins through TLR2/6 have yielded
opposing views [12,31]. Our studies demonstrated that the
addition of serum to the culture medium did not potentiate
MALP-2-induced mediator release and CD14 neutralisation did
not inhibit MALP-2-induced mediator release from any of the
three cell types. These results confirm findings that diacylated
lipoproteins do not require CD14 to signal through the TLR2/6
complex.
In addition to the role of CD14 in TLR signalling we also
investigated the role of MD-2 in the responsiveness of macro-
phages and the alveolar epithelium to LPS and MALP-2
stimulation. Our results demonstrated that neutralisation of MD-
2 completely abolished the LPS response in all three cell types.
This confirms previous studies demonstrating the importance of
MD-2 in TLR4 signalling. Crystal structure analysis of the LPS/
MD-2/TLR4 complex has shown that binding of LPS to MD-2 is
essential for receptor dimerisation and therefore subsequent
signalling [32]. Furthermore, functional in vitro studies of
intestinal epithelial cells have also demonstrated that MD-2 is
solely responsible for LPS responsiveness [33]. Unsurprisingly, we
also demonstrated that MD2 was not involved in TLR2 signalling
but these studies helped demonstrate the specificity of MD2
neutralisation on TLR4 signalling.
We have previously demonstrated that LPS activates MAP
kinases in ATII cells and macrophages [22]. However, in order to
elucidate the relative role of each of the MAP kinases in mediator
production following TLR2 and TLR4 activation, alveolar
macrophages, TT1 and ATII cells were pre-treated with inhibitors
of p38, JNK and ERK before being exposed to LPS and MALP-2.
In all experiments, inhibition of JNK or ERK was more effective
at inhibiting cytokine secretion from macrophages compared to
p38. Nevertheless, p38 was found to contribute, although the data
suggest that it plays a relatively smaller role. This in contrast to
other very recent studies [34] suggesting that ERK and p38 play a
similar role in LPS-induced TNFa secretion by human alveolar
macrophages. However, this difference in results may be due to
the presence of serum in the aforementioned study. Studies
investigating the effect of serum on MAP kinase activation in the
THP-1 monocyte cell line show that the presence of serum
increases MAP kinase phosphorylation, in particular p38 [35].
In our studies of the role of MAP kinase activation in mediator
release from TT1 and ATII cells, we demonstrated that all three
MAP kinases played a significant role in mediator release. JNK
was particularly important in TLR4-mediated MCP-1 release
from ATII cells, whereas JNK, ERK and p38 contributed to a
similar degree in TLR4-mediated TNFa and IL-8 release.
Similarly, in TT1 cells, all three MAP kinases contributed to
LPS-induced MCP-1 and IL-8 release to a similar degree.
Following TLR2 ligation, JNK appeared to play a significantly
greater role than p38 in MCP-1 and IL-8 release from TT1 cells
and IL-8 from ATII cells. Similarly, ERK played a significantly
greater role in TNF and IL-8 release from ATII cells than p38.
These results suggest that JNK and ERK may be more effective
targets than p38 for anti-inflammatory therapy during bacterial
infection.
It is interesting to note that, inhibition of ERK generally had a
greater effect on macrophages than TT1 and ATII cells. We
hypothesise that the differences in the profile of inhibition of
mediator release from ATII cells compared to macrophages may
be due to alternative pathways being activated following TLR
ligation. Previous studies in our laboratory have shown that a
significant proportion of IL-6 released following LPS stimulation
of ATII cells is dependent on feedback control by LPS-induced IL-
1b and TNFa release, which was not the case in macrophages
[22]. Subsequent ligation of the IL-1 and TNF receptors may lead
to activation of pathways that induce TNFa and MCP-1 release
via NF-kB. Studies using human epithelial cell lines [36] and
kidney cells [37] have demonstrated that IL-1b and TNFa activate
NF-kB via pathways that LPS is unable to.
In addition to the TLR2 and TLR4-induced signalling events
and cytokine and chemokine release, we have also investigated the
effect of TLR ligation on receptor protein expression and cellular
localisation, which until now, has been unclear. In the present
study, we demonstrated up-regulation of TLR4 receptors at the
Figure 8. Inhibition of MALP-2-induced cytokine release from
alveolar macrophages ATII and TT1 cells by MAP kinase
inhibitors. Cells were pre-incubated for 30 min with 10 mMo f
inhibitors of p38 (SB202190), JNK (SP600125) or ERK (PD98059) before
exposure to 100 ng/ml MALP-2 for 24 hours. TNFa (A), MCP-1 (B) and
IL-8 (C) release were measured by Luminex. Data expressed as mean 6
SE (n=4 subjects). *P,0.05, **P,0.005, ***P,0.0001.
doi:10.1371/journal.pone.0021827.g008
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in all three cell types, in particular alveolar macrophages and ATII
cells. The relative lack of increased expression of TLR4 in TT1
cells following LPS exposure may be a protective mechanism in
order to prevent an exaggerated inflammatory response. As
already mentioned, TT1 cells cover 95% of the alveolar surface
and are therefore most likely to encounter bacteria. The relatively
restrained immune response of TT1 cells to LPS exposure may be
sufficient to trigger an inflammatory response in the surrounding
ATII cells and macrophages but not sufficient enough to cause
deleterious effects from too robust an inflammatory response. Over
the time course of exposure, the signal for TLR4 protein
expression, which was detected in the outer cell membrane and
intracellularly in macrophages, and primarily intracellularly in
ATII cells, was found to increase rapidly over time, particularly
intracellularly in the perinuclear region, a process that has also
been demonstrated in monocytes [38]. It may be hypothesised that
intracellular expression of TLR4 may serve to regulate cellular
responsiveness to LPS.
It is well understood that following binding of LPS to TLR4 at
the cell surface, MyD88-dependent signalling pathways are
activated that result in MAP kinase activation and cytokine
secretion [39]. In addition, recent studies have demonstrated that
TLR4, once bound to LPS and internalised, can go on to activate
the IRF3 pathway [40]. The ability of TLR4 to signal
intracellularly may explain why cells that express high levels of
TLR4 intracellularly, such as human ATII cells discussed herein,
can respond to LPS even though there is apparently little surface
expression. Studies of the BEAS2B epithelial cell line also
demonstrated that TLR4 was expressed exclusively intracellularly
and that exposure to LPS activated MAP kinases and induced
cytokine secretion [41]. However, in these studies, levels exceeding
1 mg/ml LPS were required to elicit a robust cytokine response
and LPS exposure did not induce further TLR4 expression. This is
in marked difference to our results and suggests that there may be
differences between the two cell types. From our TLR4 and CD14
expression studies we hypothesise that ATI and ATII cells are able
to respond to LPS both at the cell surface and intracellularly
although this needs further investigation to confirm the exact
cellular location at which signalling occurs.
A particularly interesting observation in this study was that
TLR2 ligation resulted in up-regulation of TLR4 protein. The
Figure 9. Effect of LPS on alveolar macrophage and ATII cell TLR-4 protein expression. Alveolar macrophages (A) and ATII cells (B) were
exposed to LPS (100 ng/ml) over a three hour time course. Cells were fixed in methanol at 0, 15 mins, 30 mins, 1 hr, 2 hrs and 3 hrs and stained with
FITC-labelled anti-TLR4 antibody. TLR4 expression was visualised using confocal microscopy. Images were taken through the centre of the cell to
visualise cytosolic as well as cell surface expression. Data representative of 3 separate subjects.
doi:10.1371/journal.pone.0021827.g009
Figure 10. Effect of MALP-2 on alveolar macrophage and ATII cell TLR-4 protein expression. Alveolar macrophages (A) and ATII cells (B)
were exposed to MALP-2 (100 ng/ml) over a three hour time course. Cells were fixed in methanol at 0, 15 mins, 30 mins, 1 hr, 2 hrs and 3 hrs and
stained with FITC-labelled anti-TLR4 antibody. TLR4 expression was visualised using confocal microscopy. Images were taken through the centre of
the cell to visualise cytosolic as well as cell surface expression. Data representative of 3 separate subjects.
doi:10.1371/journal.pone.0021827.g010
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has been demonstrated in in vivo and in vitro models [42,43].
However, these studies have primarily focused on the effect of
TLR4 ligation on TLR2 expression. We believe this to be the first
study to show TLR2 ligation up-regulates TLR4 expression in
human alveolar macrophages and epithelial cells. Such a
mechanism may play an important role in sepsis and in chronic
lung diseases where repeated infection is common, such as COPD
and cystic fibrosis.
We were disappointed to not be able to detect TLR2-protein
despite using a number of different antibodies and staining
protocols. All three cell types respond to MALP-2, a TLR-2/6
specific ligand so must express the receptors. This suggests that the
receptors are expressed at low levels that cannot be easily detected
but are still capable of eliciting a robust response or that the
antibodies available are not suitable for this technique.
In conclusion, we have shown for the first time that the human
alveolar epithelium expresses functional CD14, MD-2 and TLR4
and responds to TLR2 ligands to produce a robust innate immune
response. Furthermore these studies of primary human alveolar
macrophages and ATII cells from the same subjects and
immortalised ATI cells demonstrate the dynamic nature of the
TLR signalling system. Thus, a single ligand can elicit distinct
responses in different cell types, following activation of one type of
TLR, via different cell signalling pathways and up-regulation of
identical TLRs. Together with our previous observations, that the
cytokine feedback control mechanisms are also different between
ATII and macrophages, we propose that the rapid response of the
respiratory unit to microbial infection critically depends on co-
ordinated action of these cells to initiate the innate immune
response.
Methods
Ethics statement
The tissue used in this study was surplus tissue obtained
following resection for lung carcinoma. Written informed consent
was obtained for all samples and the study was carried out with the
approval of the Royal Brompton and Harefield Ethical Committee
(Ref: 08/H0708/73).
Isolation of primary human alveolar macrophages and
type II epithelial cells
ATII cells and macrophages were isolated from lung tissue as
previously described (n=21 samples; [23]). Briefly, lung sections
Figure 11. Effect of LPS and MALP-2 exposure on TLR4
expression by alveolar macrophages, ATII and TT1 cells. Using
Simple PCI software analysis of images captured by confocal
microscopy, the mean fluorescent intensity of staining of individual
cells for TLR4 was measured over a 3 hour time course of exposure to
LPS (A) or MALP-2 (B). Data expressed as mean 6 SE (n=3 subjects).
*P,0.05, **P,0.002, ***P,0.0001.
doi:10.1371/journal.pone.0021827.g011
Figure 12. Cellular localisation of TLR4 protein in primary
human alveolar macrophages and ATII cells. Under high
magnification it can be seen that, in alveolar macrophages (A), there
is distinct expression of TLR4 protein at the cell surface at 30 minutes
with some intracellular staining. By three hours the intracellular staining
has increased greatly (in particular in the perinuclear region). In
contrast, in ATII cells there is strong intracellular TLR4 expression at
30 minutes which increases further by 3 hours. Similarly to the alveolar
macrophages, intracellular staining is most intense in the perinuclear
region. TLR4 expression could not be visualised in ATI cells due to low
expression.
doi:10.1371/journal.pone.0021827.g012
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less than 1610
4 cells/ml. The draining lavage was then collected
and centrifuged (290 g, 10 min, 20uC). The cell pellet was re-
suspended in serum free DCCM-1 (Cadama, UK) containing 1%
penicillin/streptomycin/glutamine (PSG; Invitrogen, Paisley, UK)
and plated in 24 well tissue culture plates (VWR, Lutterworth,
UK) at a density of 0.5610
6 macrophages/well. After three hours
macrophages had adhered and the medium was removed and the
wells were washed to remove non-adherent cells. The macro-
phages were maintained in serum free DCCM-1+1% PSG. We
have shown previously that .95% of these cells are CD68+,
phagocytic and show macrophage morphology on scanning
electron microscopy [23,44].
To isolate ATII cells, tissue was perfused and inflated with
trypsin (0.25% in HBSS; Sigma, Poole, UK) and incubated at
37uC for 45 minutes; trypsin was replaced twice during this time.
The tissue was finely chopped in the presence of newborn calf
serum (NCS; Invitrogen). The chopped tissue was then incubated
with DNase (250 mg/ml; Sigma) and the mixture passed through a
300 mm filter, followed by a 40 mm filter to remove large tissue
debris. The cell suspension was then centrifuged (290 g, 10 min,
20uC) and the resulting pellet re-suspended in DCCM-1 medium
containing 50 mg/ml DNase. These cells were incubated in tissue
culture flasks for two hours at 37uC in a humidified incubator to
allow differential adherence of contaminating mononuclear cells.
After two hours the non-adherent ATII cells were removed and
the cell suspension centrifuged as before. The cell pellet was then
re-suspended in DCCM-1 containing 10% NCS and 1% PSG at a
concentration of 0.5610
6 cells/ml. Cells were then seeded at
0.5610
6 ATII cells per well in 24 well plates coated in 1% PureCol
solution (PureCol, Leimuiden, Netherlands; Type I collagen). By
48 hours, cells had become confluent and had a purity of .95% as
previously demonstrated [45]. These cells have been thoroughly
characterised using electron microscopy, which shows that the cells
are cuboidal in morphology, have surfactant-containing lamellar
bodies, tight junctions and microvilli. Furthermore they stain
positively for the ATII cell marker alkaline phosphatase and
express surfactant proteins A and C and maintain their phenotype
for up to six days [45],[46].
Culture of immortalised ATI cells
We have created an immortalised human ATI cell line [24],
using previously published techniques [47], that shows the same
characteristics as ATI cells in vivo. Stocks of TT1 (immortalised
ATI) cells were plated in DCCM-1 media containing 10% NCS at
a density of 0.5610
6/well in a 24 well plate. Cells reached
confluency within 48 hrs.
Culture of A549 cells
Frozen stocks of A549 cells were thawed and re-suspended in
DCCM-1 containing 10% NCS at a density of 0.5610
6/well in a
24 well plate. Cells reached confluency within 48 hrs. Upon
reaching confluency cells were serum starved for 24 hours before
experiments were carried out.
Expression of CD14
Epithelial CD14 expression was measured by FACS using as
previously described [48]. 1610
6 cells were incubated for 1 hr
with FITC-conjugated anti-CD14 or IgG2a isotype control
antibody (50 mg/ml; BD Biosciences, UK). Cells were then
washed and re-suspended in FACSFlow
TM (BD Biosciences) prior
to analysis. Ten thousand events were acquired and the data
presented as the relative fluorescence, which was calculated by the
fluorescence values (median channel) of the cells stained with
FITC-conjugated anti-CD14 divided by the fluorescence values
(median channel) for the IgG2a isotype control.
Stimulation of TLR2 and TLR4 in the presence and
absence of serum
Following 24 hrs serum starvation, TT1, ATII cells and
macrophages (n=6 subjects/cell passages) were exposed to
ultrapure LPS (1, 10, 100 ng/ml; Escherichia coli 055:B5; Axxora,
UK) or MALP-2 (1, 10,100 ng/ml; Axxora, UK) in serum-free
media or media containing 10% endotoxin free NCS (Invitrogen,
UK) for 24 hours.
Neutralisation of CD14 and MD2
Cells were incubated for 1 hr with 10 mg/ml neutralising
polyclonal rabbit anti-human MD-2 (AbD serotec, UK) and
monoclonal anti-human CD14 (clone 61D3; AbCam, UK)
antibodies prior to addition of 100 ng/ml LPS or MALP-2 for
24 hrs as described above (n=4). The corresponding IgG isotypes
were used as negative controls (Abcam, UK).
Inhibition of MAP kinases
Wehave previously demonstrated LPS-induced activation of MAP
kinases in ATII cells and macrophages [22]. To assess the
contribution of MAP kinases to TLR2 and TLR4-mediated cytokine
secretion, cells were incubated for 30 minutes with 10 mMo f
commercially available inhibitors to; p38 (SB202190), ERK
(PD98059) and JNK (SP600125; Cambridge Bioscience, UK) prior
to the addition of 100 ng/ml LPS or MALP-2 for 24 hours.
Measurement of TNFa, MCP-1 and IL-8 release
Cytokine secretion was measured using the Luminex Beadly-
te
TM human multi-cytokine detection system (Millipore, UK).
Assay samples were run in triplicate as per the manufacturer’s
protocol. Sample concentrations were calculated from a standard
curve using a five-parameter regression formula.
Immunofluorescent labelling of TLR2 and TLR4
Alveolar macrophages, ATII cells and TT1 cells (n=3) were
cultured on coverslips and exposed to LPS or MALP-2 (100 ng/
ml) over a time course of 3 hours. At each time point (0, 15 min,
30 min, 1 hr, 2 hrs and 3 hrs) cells were fixed and permeabilized
in cold methanol. Following this, coverslips were blocked using
PBS containing 1% BSA (Sigma) for 1 hour at room temperature.
Cells were then incubated with either PE-labelled mouse anti-
TLR-2 or FITC-labelled mouse anti-TLR-4 (AMS Biotechnology,
Abingdon, UK) at a concentration of 5 mg/ml for two hours at
room temperature. Cells were then washed three times in PBS for
5 minutes and prepared for nuclear staining. As a negative
control, cells were incubated with the appropriate IgG carrier
protein (Dako) as described above to rule out any non-specific
effects of the staining procedure.
To stain the nucleus, 300 ml of DAPI stain (Sigma) at a
concentration of 1 mg/ml was added to each well for one minute.
The DAPI was then aspirated and the cells were washed as before.
Coverslips were mounted on microscope slides in 4.5 mlo f
Citifluor (Agar Scientific, Stansted, UK) and covered with a glass
coverslip. In order to visualise intracellular staining of TLRs,
confocal images were taken through the centre of the cells
following a scan of the whole cell layer through the Z plane.
Quantification of TLR expression
TLR expression in macrophages, TT1 and ATII cells was
measured using SimplePCI software (Digital Pixel, UK). Using
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and TLR4 expression was assessed by measuring the mean
fluorescent intensity (MFI).
Statistical analyses
Data are presented as mean 6 SE. A two-way ANOVA with
Bonferroni multiple comparison post-test was used to analyse the
concentration-dependent effects of MALP-2 and LPS in the
presence and absence of serum on cytokine and chemokine release
from TT1, ATII cells and alveolar macrophages. A two-way
ANOVA with Bonferroni multiple comparison post-test was also
use to compare the effect of TLR ligation on TLR4 expression
over time in the three cell types. A one-way ANOVA with
Bonferroni multiple comparison post-test was used to compare the
effect of MAP kinase inhibitors in each of the cell types. Unpaired
t tests were used to determine significant differences in CD14 and
MD2 neutralisation in each cells type and compare CD14
expression in the three cell types. A P value of ,0.05 was
considered to be statistically significant.
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